Association of natriuretic peptide polymorphisms with left ventricular dysfunction in Southern Han Chinese coronary artery disease patients

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 10, 2014, Pages 7148-7157

  Wu, Zhijun ^a   Xu, Min ^a   Sheng, Haihui ^b   Lou, Yuqing ^c   Su, Xiuxiu ^a   Chen, Yanjia ^a   Lu, Lin ^a   Liu, Yan ^a   Jin, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b National Engineering Center for Biochip at Shanghai   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Coronary artery disease; Heart failure; Left ventricular dysfunction; Natriuretic peptide; Polymorphism

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NPPA PROTEIN, HUMAN;

AGED; ANGIOCARDIOGRAPHY; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CHINA; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHENOTYPE; PREVENTION AND CONTROL; PROTECTION; RISK; RISK FACTOR; STATISTICAL MODEL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL NATRIURETIC FACTOR; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHINA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; HYPERLIPIDEMIAS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROTECTIVE FACTORS; RISK FACTORS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84912112322     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Armstrong PW. Left ventricular dysfunction: causes, natural history, and hopes for reversal. Heart 2000; 84 Suppl 1: i15-17.
2. Wu Z, Lou Y, Jin W, Liu Y, Lu L and Lu G. The C161T polymorphism in the peroxisome proliferator-activated receptor gamma gene (PPARgamma) is associated with risk of coronary artery disease: a meta-analysis. Mol Biol Rep 2013; 40: 3101-3112.
3. Wu Z, Lou Y, Lu L, Liu Y, Chen Q, Chen X and Jin W. Heterogeneous effect of two selectin gene polymorphisms on coronary artery disease risk: a meta-analysis. PLoS One 2014; 9: e88152.
4. Wu Z, Lou Y, Jin W, Liu Y, Lu L, Chen Q and Zhang R. The Connexin37 gene C1019T polymorphism and risk of coronary artery disease: a meta-analysis. Arch Me Res 2014; 45: 21-30.
5. Cea LB. Natriuretic peptide family: new aspects. Curr Med Chem Cardiovas Hematol Agents 2005; 3: 87-98.
6. Rubattu S, Sciarretta S, Valenti V, Stanzione R and Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21: 733-741.
7. Lang RE, Tholken H, Ganten D, Luft FC, Ruskoaho H and Unger T. Atrial natriuretic factor--a circulating hormone stimulated by volume loading. Nature 1985; 314: 264-266.
8. Mohammed AA and Januzzi JL Jr. Natriuretic peptides in the diagnosis and management of acute heart failure. Heart Fail Clin 2009; 5: 489-500.
9. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, Edelman S, Henry R and Maisel A. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003; 26: 2081-2087.
10. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, White HD, Fox KA, Califf RM and Braunwald E. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. Jama 2005; 294: 2866-2871.
11. Clerico A and Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50: 33-50.
12. Wang D, Oparil S, Feng JA, Li P, Perry G, Chen LB, Dai M, John SW and Chen YF. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension 2003; 42: 88-95.
13. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H and Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000; 97: 4239-4244.
14. Del Greco MF, Pattaro C, Luchner A, Pichler I, Winkler T, Hicks AA, Fuchsberger C, Franke A, Melville SA, Peters A, Wichmann HE, Schreiber S, Heid IM, Krawczak M, Minelli C, Wiedermann CJ and Pramstaller PP. Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene cluster. Hum Mol Genet 2011; 20: 1660-1671.
15. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O and Wang TJ. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009; 41: 348-353.
16. Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D, Gigante B, Pirisi A, Brunetti E and Volpe M. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 2004; 35: 814-818.
17. Liguori A, Di Gregorio F, Napoli C, D'Armiento FP, Posca T, Di Benedetto A, Di Ieso N, Di Paolo E and Ferrara A. Atrial natriuretic factor and sympathetic activation in human heart failure. Riv Eur Sci Med e Farmacol 1994; 16: 61-67.
18. Larifla L, Maimaitiming S, Velayoudom-Cephise FL, Ferdinand S, Blanchet-Deverly A, Benabdallah S, Donnet JP, Atallah A, Roussel R and Foucan L. Association of 2238T >C polymorphism of the atrial natriuretic peptide gene with coronary artery disease in Afro-Caribbeans with type 2 diabetes. Am J Hypertens 2012; 25: 524-527.
19. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C and Arnett DK. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. Jama 2008; 299: 296-307.
20. Vassalle C, Andreassi MG, Prontera C, Fontana M, Zyw L, Passino C and Emdin M. Influence of ScaI and natriuretic peptide (NP) clearance receptor polymorphisms of the NP System on NP concentration in chronic heart failure. Clin Chem 2007; 53: 1886-1890.
21. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G, Volpe M and Stella P. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 2006; 48: 499-505.
22. Ellis KL, Newton-Cheh C, Wang TJ, Frampton CM, Doughty RN, Whalley GA, Ellis CJ, Skelton L, Davis N, Yandle TG, Troughton RW, Richards AM and Cameron VA. Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol 2011; 50: 695-701.
23. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Gardner TJ, Garson A Jr, Russell RO Jr, Ryan TJ and Smith SC Jr. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 1999; 99: 2345-2357.
24. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL and Williams DO. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
25. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH and Weissman NJ. American Society of Echocardiography. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004; 17: 1086-1119.
26. Nadir MA, Dow E, Davidson J, Kennedy N, Lang CC and Struthers AD. Myocardial ischaemia is associated with an elevated brain natriuretic pepide level even in the presence of left ventricular systolic dysfunction. Eur J Heart Fail 2014; 16: 56-67.
27. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr and Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
28. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
29. Shi YY and He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-98.
30. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM and Schaid DJ. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55: 56-65.
31. Stram DO, Leigh Pearce C, Bretsky P, Freedman M, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE and Thomas DC. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003; 55: 179-190.
32. Schaid DJ, Rowland CM, Tines DE, Jacobson RM and Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
33. Pattin KA, White BC, Barney N, Gui J, Nelson HH, Kelsey KT, Andrew AS, Karagas MR and Moore JH. A computationally efficient hypothesis testing method for epistasis analysis using multifactor dimensionality reduction. Genetic epidemiology 2009; 33: 87-94.
34. Hahn LW, Ritchie MD and Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19: 376-382.
35. Fox AA, Collard CD, Shernan SK, Seidman CE, Seidman JG, Liu KY, Muehlschlegel JD, Perry TE, Aranki SF, Lange C, Herman DS, Meitinger T, Lichtner P and Body SC. Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology 2009; 110: 738-747.
36. Martinez-Rumayor A, Richards AM, Burnett JC and Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol 2008; 101: 3-8.
37. Onuoha GN, Nicholls DP, Patterson A and Beringer T. Neuropeptide secretion in exercise. Neuropeptides 1998; 32: 319-325.
38. Dessi-Fulgheri P, Sarzani R and Rappelli A. Role of the natriuretic peptide system in lipogenesis/lipolysis. Nutr, Metab Cardiovasc Dis 2003; 13: 244-249.
39. Kohno M, Yasunari K, Maeda K, Kano H, Minami M, Hanehira T and Yoshikawa J. Effects of cardiac natriuretic peptides on oxidized low-density lipoprotein- and lysophosphatidylcholine-induced human mesangial cell migration. Hypertension 2000; 35: 971-977.
40. Liang F, Kapoun AM, Lam A, Damm DL, Quan D, O'Connell M and Protter AA. B-Type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells. Endocrinology 2007; 148: 3722-3729.
41. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697.
42. Sisson DD. Neuroendocrine evaluation of cardiac disease. Vet Clin North Am Small Anim 2004; 34: 1105-1126.
43. Schrier RW and Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-585.